Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors
Oral iron supplementation in patients with background therapy including a SGLT2i (vs. SGLT2i non-users) was associated with a greater increase in hemoglobin and hematocrit. These results suggest that patients with HF or CKD patients treated with SGLT2i might have an enhanced erythropoietic response to oral iron supplementation.
Authors
- António Angélico‐Gonçalves (ORCID: https://orcid.org/0000-0003-2765-1738)
- Fernando Friões (ORCID: https://orcid.org/0000-0002-0856-8552)
- Milton Packer
- Hugo Diniz (ORCID: https://orcid.org/0000-0002-8476-1338)
- Christoforos K. Travlos (ORCID: https://orcid.org/0000-0002-7797-8141)
- Pedro Marques (ORCID: https://orcid.org/0000-0002-1120-5461)
- Michael A. Tsoukas (ORCID: https://orcid.org/0000-0002-8326-7274)
- Paula Matias
- Thomas A. Mavrakanas (ORCID: https://orcid.org/0000-0002-3368-247X)
- João Pedro Ferreira (ORCID: https://orcid.org/0000-0002-2304-6138)
- Abhinav Sharma (ORCID: https://orcid.org/0000-0002-6768-0296)
- Francisco Vasques-Nóvoa
Institutions
- Inserm (FR)
- Universidade do Porto (PT)
- McGill University Health Centre (CA)
- Baylor University Medical Center (US)
- Hospital de São João (PT)
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Centro Hospitalar de Vila Nova de Gaia (PT)
- French Clinical Research Infrastructure Network (FR)
- Imperial College London (GB)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1007/s00392-025-02685-6
- Citations
- 2
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Universidade do Porto